The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model

Pancreatic cancer often has a very poor prognosis, even after complete resection. The recurrence of hepatic and peritoneal metastases is an important prognostic factor; therefore, the development of improved adjuvant therapy is urgently required. Mesothelin is a cell surface glycoprotein whose expre...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizukami, Tatsuzo, Kamachi, Hirofumi, Fujii, Yuki, Matsuzawa, Fumihiko, Einama, Takahiro, Kawamata, Futoshi, Kobayashi, Nozomi, Hatanaka, Yutaka, Taketomi, Akinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173461/
https://www.ncbi.nlm.nih.gov/pubmed/30333914
http://dx.doi.org/10.18632/oncotarget.26117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173461/
https://www.ncbi.nlm.nih.gov/pubmed/30333914
http://dx.doi.org/10.18632/oncotarget.26117

Ejemplares similares